top of page

WE CONNECT THE BEST TREATMENTS WITH THE BRIGHTEST MINDS

home_fondo_link_barra.jpg

MEDSIR is a company founded by scientific experts in 2012. We are dedicated to the design and management of strategic clinical trials in oncology, from study conception to the publication of study results.

 

MEDSIR favors a new model for collaborative clinical research in oncology development that aims to combine the highest scientific value with the strategic development of novel cancer treatments, with the final goal of benefiting cancer patients worldwide. Our goal is to generate win-win scenarios for all stakeholders involved in independent clinical research.


 
TOGETHER WE CAN BUILD A BRIGHTER FUTURE

HOW CAN WE HELP YOU

home_fondo_link_barra.jpg

Our international team of high-level clinicians and research experts are passionate about collaborating with medical oncologists and pharmaceutical companies to develop the best treatments for patients as quickly as possible.

13 YEARS OF INNOVATIVE CLINICAL RESEARCH

home_fondo_link_barra.jpg

From Barcelona to Boston, and with a presence in over 14 countries, today we’re celebrating more than just an anniversary. We’re celebrating 13 years dedicated to a mission that drives us every day: advancing cancer research globally through innovation, scientific excellence and international collaboration.

MEDSIR IN NUMBERS

home_fondo_link_barra.jpg

>40
INDUSTRY FUNDERS

>196  
SITES

>65
TRIALS DEVELOPED

>615  
RESEARCH
COLLABORATORS

>1000  
IDEAS
GENERATED

>120  
STAFF
DEDICATED

>2633  
PATIENTS
RECRUITED

OUR STUDIES

home_fondo_link_barra.jpg

Some examples of MEDSIR ideas matured into strategic clinical trials.

3d-rendering-luxury-new-background-white-honeycomb-hexagon-pattern-honeycomb-3d-illustrati

PHERGAIN

BREAST

Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: A FDG-PET response-adapted strategy

3d-rendering-luxury-new-background-white-honeycomb-hexagon-pattern-honeycomb-3d-illustrati

TUXEDO-3

LUNG & BREAST

HER3-DXD in patients with active BMs from metastatic breast cancer and NSCLC, and in patients with leptomeningeal disease from advanced solid tumors.

3d-rendering-luxury-new-background-white-honeycomb-hexagon-pattern-honeycomb-3d-illustrati

ADELA

BREAST

Elacestrant + everolimus in patients with ER+/HER2-, esr1mut, advanced breast cancer progressing on endocrine therapy and CDK4/6 inhibitors

3d-rendering-luxury-new-background-white-honeycomb-hexagon-pattern-honeycomb-3d-illustrati

PECATI

THYMIC

Phase II study of the combination of Pembrolizumab and Lenvatinib in pre-treated thymic carcinoma

close-up-view-young-female-doctor-writing-medical-charts-with-tablet-office-room.jpg

For any question or suggestion,
we are here for you.

Transparency:
The Ethical Channel for Raising Concerns

bottom of page